Iloprost (Iloprost Trometamol)

Iloprost acts as a selective prostacyclin (IP) receptor agonist. Activation of these receptors raises cyclic AMP in vascular smooth‑muscle cells, causing vasodilation and inhibiting platelet aggregation, which improves blood flow in the pulmonary circulation and peripheral vessels.

The dosing regimen for Iloprost is individualized. A qualified prescriber determines the appropriate infusion rate, concentration, and duration based on the patient’s clinical condition, response, and tolerance.

Safety data for Iloprost in pregnancy and lactation are limited. The product is classified as pregnancy category unknown, and it is generally advised to avoid use unless the potential benefit justifies the potential risk to the fetus or infant.

To request Iloprost, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and import documentation.

Iloprost is a synthetic prostacyclin analog administered intravenously, offering rapid onset and short half‑life. Compared with longer‑acting agents like epoprostenol, Iloprost may allow more flexible infusion schedules but requires careful monitoring for hypotension and bleeding.

Iloprost solution for injection should be stored refrigerated at 2‑8 °C. Keep the vial in its original packaging, protect it from light, and do not freeze or shake the product before use.

Iloprost is given as an intravenous infusion. The solution is diluted according to the prescriber’s instructions and administered via a controlled infusion pump over a prescribed period, typically in a clinical setting with continuous monitoring.

Serious risks include severe hypotension, pulmonary edema, and bleeding complications. Patients should be monitored closely for sudden drops in blood pressure, signs of fluid overload, and any unexpected bleeding during treatment.

Iloprost is contraindicated in patients with active bleeding, uncontrolled severe hypotension, or known hypersensitivity to the drug or its excipients. Caution is also advised for individuals with severe renal impairment or during pregnancy.